Showing 1541-1550 of 2152 results for "".
- Lilly Begins World’s First Human Study of Antibody to Treat COVID-19https://modernod.com/news/lilly-begins-worlds-first-human-study-of-antibody-to-treat-covid-19/2477853/Eli Lilly said that the first patients have been dosed in a phase 1 trial investigating the experimental antibody LY-CoV555 for the treatment of COVID-19. The company, which is developing the drug with partner AbCellera, noted that the move marks the world’s first study of a potential antib
- Santen Receives Canadian Drug Expert Committee Reimbursement Recommendation for Verkazia Eye Dropshttps://modernod.com/news/santen-receives-canadian-drug-expert-committee-reimbursement-recommendation-for-verkazia-eye-drops/2477114/Santen Canada announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) released a reimbursement recommendation for Verkazia (cyclosporine 0.1%) eye drops. This reimbursement recommendation marks an important step towards providin
- Katena Announces the Acquisition of Micro Medical Instrumentshttps://modernod.com/news/katena-announces-the-acquisition-of-micro-medical-instruments/2477093/Katena Products announced the purchase of Micro Medical Instruments (MMI), a medical contract manufacturing service. Terms of the deal were not disclosed. “The acquisition of MMI, Inc. will strengthen Katena’s manufacturing capability,” Mark Fletcher, CEO of Katena Products, said i
- Cassini to Reveal New Cassini Device at ESCRShttps://modernod.com/news/cassini-to-reveal-new-cassini-device-at-the-escrs-in-paris/2476880/Cassini announced that it will reveal its new Cassini device at the 37th Congress of European Society of Cataract and Refractive Surgeons in Paris. This product introduction marks the next chapter of product design, with latest camera technology, improved patient comfort and great usability.
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmologyhttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology/2476783/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education, and patient care, this year marks the 18th time that Bascom P
- Post-Approval Study Finds No Surprises With Argus II Retinal Implanthttps://modernod.com/news/post-approval-study-finds-no-surprises-with-argus-ii-retinal-implant/2476647/Post-approval follow-up of the Argus II Retinal Prosthesis System shows safety and visual function outcomes similar to those in previous trials, according to a company-funded study, as reported in Reuters. With a CE mark granted in 2011, the device became the first retinal prosthesis to b
- UnitedHealthcare Vision Plans Rank Highest in Customer Satisfaction in J.D. Power Reporthttps://modernod.com/news/unitedhealthcare-vision-plans-rank-highest-in-customer-satisfaction-in-j-d-power-report/2476287/UnitedHealthcare Vision plans tied for highest in customer satisfaction among the nation’s vision carriers, according to the J.D. Power 2018 Vision Plan Satisfaction Report. This marks the fifth time in 6 years that UnitedHealthcare Vision has earned the highest ranking among vision plans.
- Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMDhttps://modernod.com/news/ranibizumab-and-aflibercept-prompt-comparable-visual-gain-in-amd/2476339/In patients with neovascular age-related macular degeneration (AMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers, as reported by Reuters. In a January 24 online paper in JAMA Ophthalmology, Dr. Mark C. Gillies of Sy
- Takeda CEO Optimistic About Growth Prospects as Drugmaker Finalizes Shire Takeoverhttps://modernod.com/news/takeda-ceo-optimistic-about-growth-prospects-as-drugmaker-finalizes-shire-takeover/2476205/Takeda announced that it has completed its $62-billion acquisition of Shire. Christophe Weber, chief executive of Takeda, stated “this marks a significant moment in [our] history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicin
- LumiThera and Optos Announce Collaboration to Commercialize the Valeda Light Delivery System for Treating Dry AMD in Europehttps://modernod.com/news/lumithera-and-optos-announce-collaboration-to-commercialize-the-valeda-light-delivery-system-for-treating-dry-amd-in-europe/2479740/LumiThera announced a distribution agreement with Optos to exclusively distribute the Valeda Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. The announcement follows the recent CE Mark certification for the European Union (EU) for th